Cancer testing
CellGeneMedix develops proprietary molecular diagnostic technologies that bring precision to cancer treatment selection, risk stratification, and infectious disease detection. Our work is backed by a patent portfolio, including a granted Korean patent and pending U.S. applications, and built on deep expertise across the U.S. and Korean diagnostic markets.
Longevity Medicine
At CellGeneMedix, we are developing advanced genetic testing to identify and predict risk for major aging-related diseases, including cancer, cardiovascular, brain, liver and kidney disease. These insights can help guide earlier screening and prevention.
GoodAg COVID-19 test
Kras/Braf Real time PCR test
CTC Analysis
Stem cells and Cosmetics
Immunotherapy and Cell Vaccine
We welcome research collaborations on our diagnostic products, including validation studies with laboratories and institutions. Contact research@cellgenemedix.com.
Quality management
The products we distribute are manufactured by our Korean partners, in accordance with Good Manufacturing Practice (GMP) and ISO 9001 & 13485 standards, and carry the EU CE mark for Europe. They are not authorized or cleared for use in the United States.
Therapeutic & Diagnostic Products
Our diagnostic tools detect actionable genomic alterations and infectious agents using advanced methods like PCR and DNA microarrays, offering molecular profiling for personalized care.
Facilities
Our U.S. office is located in Newark, New Jersey. The products we distribute are manufactured in Korea by affiliates in a GMP-certified facility. We work with partner laboratories for research and product validation.